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AbstrAct
Nephrotoxicity is a common toxic side-effect of chemotherapeutic alkylating 
agents. Although the base excision repair (BER) pathway is essential in repairing DNA 
alkylation damage, under certain conditions the initiation of BER produces toxic repair 
intermediates that damage healthy tissues. We have shown that the alkyladenine 
DNA glycosylase, Aag (a.k.a. Mpg), an enzyme that initiates BER, mediates alkylation-
induced whole-animal lethality and cytotoxicity in the pancreas, spleen, retina, and 
cerebellum, but not in the kidney. Cytotoxicity in both wild-type and Aag-transgenic 
mice (AagTg) was abrogated in the absence of Poly(ADP-ribose) polymerase-1 
(Parp1). Here we report that Parp1-deficient mice expressing increased Aag (AagTg/
Parp1-/-) develop sex-dependent kidney failure upon exposure to the alkylating 
agent, methyl methanesulfonate (MMS), and suffer increased whole-animal lethality 
compared to AagTg and wild-type mice. Macroscopic, histological, electron microscopic 
and immunohistochemical analyses revealed morphological kidney damage including 
dilated tubules, proteinaceous casts, vacuolation, collapse of the glomerular tuft, 
and deterioration of podocyte structure. Moreover, mice exhibited clinical signs of 
kidney disease indicating functional damage, including elevated blood nitrogen urea 
and creatinine, hypoproteinemia and proteinuria. Pharmacological Parp inhibition 
in AagTg mice also resulted in sensitivity to MMS-induced nephrotoxicity. These 
findings provide in vivo evidence that Parp1 modulates Aag-dependent MMS-induced 
nephrotoxicity in a sex-dependent manner and highlight the critical roles that Aag-
initiated BER and Parp1 may play in determining the side-effects of chemotherapeutic 
alkylating agents.
INtrODUctION
The kidney is essential for excretion of waste and 
maintenance of proper osmotic and oncotic pressure; these 
functions require a properly functioning filtration unit 
comprised of the glomerulus and surrounding Bowman’s 
capsule. Blood is filtered within the filtration unit; 
protein, cells, and specific concentrations of chemicals 
are retained, whereas waste and extra fluid is passed to 
the renal tubules to become urine. One common feature 
of glomerular dysfunction is loss of protein from the 
blood (hypoproteinemia) accompanied by increased 
urinary protein (proteinuria). Glomerular dysfunction 
can cause chronic kidney disease and eventually end-
stage renal disease (ESRD), requiring dialysis or kidney 
transplantation. Various causes include genetic mutations, 
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autoimmunity, infections, environmental exposures or 
any combination thereof (reviewed in [1-4]). Pathological 
changes damaging the glomerular filtration apparatus are 
responsible for 90% of ESRD, resulting in ~$20 billion in 
yearly health costs in the USA [5].
The glomerular filtration unit has three layers: 
the visceral epithelial cells (podocytes), the glomerular 
basement membrane, and parietal endothelial cells; proper 
communication and function of all three components is 
required for glomerular function. Podocytes, the most 
essential cell-type for glomerular filtration, possess 
interdigitating foot processes that form filtration slits 
called slit diaphragms (reviewed in [6]). Loss of the 
slit diaphragm through effacement of the podocyte foot 
processes is sufficient to cause proteinuria and kidney 
damage, emphasizing the importance of podocytes in 
proper kidney function [7]. Various podocytopathies play 
a dominant role in glomerular diseases [2].
Some cancer chemotherapeutic agents, including 
alkylating agents, induce nephrotoxicity. For example, 
oxazaphosphorines, used in the treatment of certain 
leukemias, lymphomas and solid tumors, result in 
significant nephrotoxicity [8-10]. Such off-target toxicity 
is dose-limiting, thus reducing efficacy. 
Alkylating agents represent one class of commonly-
utilized chemotherapeutic agents that generate numerous 
types of alkylated DNA base lesions, including O6-
alkylguanine (O6alkG), 7-alkylguanine (7alkG) and 
3alkyladenine (3alkA). The induction of cell death in 
rapidly-dividing cells by these toxic DNA lesions underlies 
the effectiveness of alkylators as cancer chemotherapeutic 
agents. The base excision repair (BER) pathway repairs 
many alkylated DNA base lesions [11]. BER is initiated 
by the recognition and excision of alkylated DNA base 
lesions by the alkyladenine DNA glycosylase, Aag (a.k.a. 
Mpg). After base excision, an AP endonuclease (Ape1) 
hydrolyzes the phosphodiester backbone at the abasic 
site, generating a single-stranded DNA break (SSB) with 
3’OH and 5’deoxyribose-5-phosphate (5’dRP) termini. 
Poly(ADP-ribose) polymerase-1 (Parp1) acts as a SSB 
sensor, and, upon binding a SSB, is activated to catalyze 
the addition of long polymers of ADP-ribose to itself 
and several other proteins. The poly(ADP-ribose) chains 
are thought to recruit downstream BER enzymes: DNA 
polymerase β (Pol β) that removes the 5’dRP terminus and 
extends the missing nucleotide from the 3’OH, and either 
DNA Ligase I or the Xrcc1/LigaseIIIα complex that seal 
the remaining nicked DNA to complete BER.
Although BER can repair DNA alkylation damage, 
under certain conditions the initiation of BER can generate 
toxic repair intermediates that cause damage to healthy 
tissues. Recently, using mouse genetic models, we 
demonstrated the importance of both Aag and Parp1 in 
modulating in vivo alkylation sensitivity. Modest increases 
in Aag activity in a transgenic mouse model (AagTg mice) 
increased susceptibility to the alkylating agent, methyl 
methanesulfonate (MMS), for both whole-animal survival 
and tissue damage in a specific subset of tissues [12, 13]. 
The Aag-mediated alkylation sensitivity of these tissues, 
for both wild-type (WT) and AagTg mice, is entirely 
Parp1-dependent, being wholly prevented by Parp1 
deficiency. Here, we show that although Parp1 deficiency 
protects against Aag-dependent, MMS-mediated 
tissue degeneration in the pancreas, spleen, retina, and 
cerebellum [12], Parp1 deficiency is surprisingly unable 
to protect against MMS-mediated whole-animal lethality. 
In fact, AagTg/Parp1-/- mice exhibit greater morbidity and 
lethality following MMS treatment as compared to AagTg 
mice. Strikingly, following MMS treatment, AagTg/Parp1-
/- mice exhibit severe glomerular damage, suggesting 
a novel role for Aag and Parp1 in modulating the renal 
toxicity of alkylating agents. 
Numerous animal models of acquired podocyte 
diseases have been described (reviewed in [14, 15]). 
MMS-treated AagTg/Parp1-/- mice represent a new model 
of glomerular disease and may provide insight into many 
types of human glomerular diseases. Further, the induction 
of nephrotoxicity by MMS is novel and the importance 
of Parp1 and Aag in modulating responses is especially 
relevant, given the recent surge in the use of PARP 
inhibitors for multiple clinical indications and the wide 
range of AAG activity in the human population [12, 16, 
17]. 
rEsULts
AagTg and Parp1-/- alleles display synthetic 
lethality for alkylation-induced animal toxicity
AagTg mice, expressing higher than WT levels 
of Aag, display increased sensitivity to MMS toxicity 
compared to WT mice, at the whole-animal level and 
in numerous tissues including the cerebellum, retina, 
and pancreas, but not kidney [12, 13]. However, Parp1 
deficiency completely suppresses MMS-mediated damage 
to these tissues in both WT and AagTg mice [12]. To 
determine whether Parp1 deficiency also protects against 
whole-body alkylation sensitivity in AagTg mice, we 
determined the LD50 of the alkylating agent MMS in WT, 
Parp1-/-, AagTg, and AagTg/Parp1-/- mice. Surprisingly, 
although alkylation-induced damage in numerous tissues 
is suppressed in AagTg/Parp1-/- mice [12], whole-animal 
toxicity is not suppressed; rather, the animals are more 
susceptible to MMS-induced whole-animal lethality. The 
MMS LD50 for AagTg mice is 80 mg/kg as we previously 
reported [12], and 66 mg/kg for AagTg/Parp1-/- mice 
(Table 1). Parp1-/- mice exhibit the same whole-body 
sensitivity to MMS as WT (LD50 200 mg/kg). Remarkably, 
during a 30-day (d) survival experiment post-MMS 
treatment (75 mg/kg, a dose slightly below the LD50 of 
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AagTg mice), we observed that AagTg/Parp1-/- mice began 
to lose significant body weight (Figure 1A) and exhibited 
signs of severe disease, including lethargy, a hunched 
posture, and cachexia (losing ~20% of initial BW) by 15d 
post-MMS treatment; all AagTg/Parp1-/- mice succumb 
within 30d (Figure 1B-1C).
AagTg mice combined with either the Parp1-/- 
allele or Parp inhibition are susceptible to MMs-
mediated renal toxicity
To investigate causa mortis in AagTg/Parp1-/- mice, 
we examined a panel of tissues at gross and histological 
levels 14d post-MMS. Remarkably, only the kidneys 
displayed alkylation-induced pathology. MMS-treated 
AagTg/Parp1-/- kidneys were smaller and paler compared 
to untreated and MMS-treated WT mice (Figure 2A). 
Accordingly, severe histological changes were observed. 
Under low magnification, we observed large, pink, 
proteinaceous casts that resulted in dilation of the kidney 
tubules (Figure 2B). High magnification revealed severe 
glomerular abnormalities, including vacuolation and loss 
of the Bowman’s space (Figure 2B). Periodic acid-Schiff 
(PAS) staining shows a glomerular structure severely 
disturbed in AagTg/Parp1-/- mice post-MMS, as evident 
by vacuolation and glomerular tuft collapse (Supplemental 
Figure 1). No evidence of kidney disease was seen in 
MMS-treated WT, AagTg (Figure 2B and Supplemental 
Figure 1) or Parp1-/- (not shown) mice. Moreover, no other 
tissues from MMS-treated AagTg/Parp1-/- mice revealed 
histological abnormalities (not shown) at 14d. AagTg/
Parp1-/- kidneys stained with PAS, toludine blue and 
phosphotungstic acid-hematoxilin (PTAH) 14d post-MMS 
showed no evidence of abnormal glomerular cellular 
accumulations, intravascular fibrin thrombi, matrix 
deposits, or significant fibrosis (Supplemental Figure 2). 
AagTg mice treated with ABT-888 (a.k.a. Veliparib), 
a clinically-relevant PARP inhibitor, exhibit MMS-
mediated renal toxicity similar to AagTg/Parp1-/- mice 
(Figure 3) indicating that Parp inhibition was sufficient to 
sensitize AagTg mouse kidneys to MMS. However, renal 
toxicity was reduced in MMS/ABT-888-treated AagTg 
mice compared to MMS-treated AagTg/Parp1-/- mice, with 
affected glomeruli and protein casts being less prevalent. 
Consistent with the reduced severity of the kidney 
phenotype, MMS/ABT-888-treated AagTg mice exhibited 
lower whole-body sensitivity compared to AagTg/Parp1-
/- mice; at 20d post-MMS treatment, no AagTg mice were 
moribund and >80% of the AagTg mice showed no sign of 
distress through 30d post-MMS (not shown). 
Having shown that AagTg mice combined with 
either the Parp1-/- allele or Parp inhibition are susceptible 
to MMS-mediated renal toxicity, we determined 
whether this toxicity correlates with the accumulation 
of BER intermediates and lack of Parp activity. The Aag 
glycosylase generates potentially toxic abasic (AP) sites 
that can block replication and transcription [18, 19], and 
their cleavage by AP endonuclease generates highly toxic 
DNA single-strand breaks [20]; indeed, until the final 
ligation step of BER, these toxic lesions are present in 
DNA. Thus, if BER is initiated under conditions where the 
subsequent processing of BER intermediates is limiting, 
i.e. by Parp deficiency, this can result in cell death and 
tissue damage; under these circumstances cells are said 
to have an imbalanced BER pathway [11]. Indeed, at 3 
hours post-MMS treatment, AagTg kidney DNA contained 
twice as many AP sites as WT kidney DNA (Supplemental 
Figure 3A). Consistent with these findings, at 6 hours 
post-MMS treatment, Parp activity was highly increased 
in AagTg kidneys compared to WT kidneys (Supplemental 
Figure 3B). In both WT and AagTg kidneys, Parp activity 
peaks at 24 hours post-MMS treatment and returns to basal 
levels within 48 hours post-MMS treatment. Conversely, 
although AagTg/Parp1-/- kidney DNA had high levels of 
AP sites similarly to AagTg kidney DNA at 3 hours post-
MMS treatment (Supplemental Figure 3A), no increase in 
Parp activity was observed in AagTg/Parp1-/- kidneys at 
any time point (Supplemental Figure 3B). These findings 
support the hypothesis that an imbalanced BER pathway 
can be detrimental for the kidney. 
Progression of MMs-mediated renal toxicity in 
AagTg/Parp1-/- mice
We examined the kinetics of MMS-induced kidney 
damage by monitoring kidney toxicity at 3, 5, 7 and 14d 
post-MMS. We assessed the glomerulus, renal tubules and 
Bowman’s capsule following histopathological criteria 
listed in Supplemental Table 1. No histopathological 
abnormalities were observed at any time point in WT 
mice and in AagTg/Parp1-/- mice at 3d or 5d post-MMS 
(Figure 4A-4C). However, by 7d we observe abnormalities 
in AagTg/Parp1-/- kidneys. One obvious change within 
the renal tubules at 7d post-MMS is tubule dilation and 
presence of proteinaceous casts (Figure 4C). By 14d 
there is also evidence of reactive changes in the tubules, 
including mild degeneration and hyperplasia (Figure 4C). 
Consistent with reactive regeneration, epithelial mitotic 




Parp1 -/- 200 mg/kg
AagTg 80 mg/kg
AagTg/Parp1-/- 66 mg/kg
# as determined by Deichmann and LeBlanc method 
(1943). MMS, methyl methanesulfonate
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Figure 1: Parp1 deficiency results in increased overall whole-body sensitivity to MMS toxicity. A. Body weight, as 
percentage of initial body weight following MMS treatment (75 mg/kg), is illustrated for WT (n = 17), Parp1-/- (n = 9), AagTg (n = 19), and 
AagTg/Parp1-/- (n = 22) mice at different time points. Representative data from two experiments are shown. B. Representative pictures of 
mouse body condition 14 days post-MMS treatment (75 mg/kg). C. Kaplan Meier survival curves are shown for WT (n =  9), Parp1-/- (n = 
7), AagTg (n = 6), and AagTg/Parp1-/- (n = 12) mice following treatment with MMS (75 mg/kg).
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figures are also observed (Supplemental Figure 4). The 
glomerulus exhibits histological abnormalities as early 
as 7d post-MMS, including vacuolation of podocytes or 
parietal cells and capillary collapse of the lumen (Figure 
4D). By 14d, glomeruli in AagTg/Parp1-/- mice exhibit 
significant increases in the histological scores of podocyte 
or parietal cell hyperplasia (p = 0.0005), vacuolation 
(p = 0.001) and capillary lumen collapse (p < 0.05). 
At 14d post-MMS, additional glomerular pathological 
abnormalities appear, including crescent formation 
(Figure 2B and 4A), a phenomenon commonly observed 
in crescentic glomerulonephritis in both humans and mice 
[21-23]. 
AagTg/Parp1-/- mice exhibit clinical markers of 
kidney disease
We next investigated whether kidney abnormalities 
observed at the histological level were accompanied 
by clinical markers of disease. Serum analytes were 
measured before treatment, 14d post-MMS, and when 
the mice exhibited morbidity post-MMS. We observe a 
trend toward higher serum levels of blood urine nitrogen 
(BUN) in AagTg/Parp1-/- mice 14d post-MMS compared 
to WT mice (p = 0.157) (Figure 5A); this trend became 
significant in moribund AagTg/Parp1-/- mice (p < 0.005) 
(Figure 5A). Levels of blood creatinine, another marker 
of kidney damage, did not change significantly post-MMS 
treatment (Figure 5B). 
Serum albumin levels, a marker of glomerular 
function, displayed dramatic decreases following MMS 
in AagTg/Parp1-/- mice compared to treated WT mice or 
Figure 2: AagTg/Parp1-/- mice exhibit MMS-mediated kidney damage. A. Representative images of kidneys following MMS 
treatment. Kidneys from a moribund AagTg/Parp1-/- mouse and a WT mouse 14 days post-MMS treatment (75 mg/kg) are shown. B. H&E 
analysis of kidneys from WT, AagTg, Parp1-/-, and AagTg/Parp1-/- mice 14 days following MMS treatment (75 mg/kg). Magnification is 
200X (scale bar 50 µm) and 600x (scale bar 10 µm); asterisks indicate proteinaceous casts, the black arrow indicates vacuolation, and 
yellow arrowhead indicates parietal and visceral epithelial hypertrophy/hypercellularity with vacuolation, tuft adhesions, capillary collapse 
and crescent formation.
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untreated AagTg/Parp1-/- mice (Figure 5C). In addition, 
we observed high levels of a ~65 kDa protein, consistent 
with the size of albumin, in the AagTg/Parp1-/- mouse 
urine 7d post-MMS (Figure 5D). Together, these data 
indicate that albumin is not properly maintained in the 
serum, but is likely accumulating in the kidney tubules 
Figure 3: AagTg mice treated with a Parp inhibitor exhibit MMs-mediated renal toxicity similar to AagTg/Parp1-/- 
mice. H&E stained images of kidneys from WT, AagTg, and AagTg/Parp1-/- mice 20 days (A) and 30 days (B) following MMS (75 mg/kg) 
and/or ABT-888 (10 mg/kg) treatment as indicated. ABT-888 was administered 1 hour prior and 5 days post-MMS treatment. Magnification 
is 100X, 200X (scale bar 50 µm) and 600x (scale bar 10 µm); MMS- and ABT-888-treated AagTg mice show islands of pink proteinaceous 
casts, dilation of the kidney tubules, and few glomeruli with severe abnormalities (including vacuolation and the loss of Bowman’s space) 
as seen in AagTg/Parp1-/- mice post-MMS treatment. 
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Figure 4: Kinetics of kidney damage in AagTg/Parp1-/- mice following MMS treatment. A. H&E-stained images of kidneys 
from WT and AagTg/Parp1-/- mice under untreated conditions and 7 and 14 days following MMS treatment (75 mg/kg). Magnification is 
600X (scale bar 10 µm). B. Total histopathology scores for glomerular damage (podocyte/parietal cell hyperplasia/hypertrophy, vacuolation, 
capillary lumen collapse, tuft adhesions and/or sclerosis) and tubular damage (degeneration, cast formation, hyperplasia) is shown at five 
time points, post MMS treatment (75 mg/kg); untreated (WT, n = 5 and AagTg/Parp1-/-, n = 7), 3 days (WT, n = 3 and AagTg/Parp1-/-, n = 
2), 5 days (WT, n = 7 and AagTg/Parp1-/-, n = 10), 7 days (WT, n = 5 and AagTg/Parp1-/-, n = 7 and 14 days (WT, n = 10 and AagTg/Parp1-/-, 
n = 11). Histopathological scores for C. renal tubule criteria and D. glomerular criteria. 
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as proteinaceous casts, and ultimately leaking into the 
urine of MMS-treated AagTg/Parp1-/- mice. The albumin 
leakage in the urine 7d post-MMS is consistent with 
histopathological changes within the glomerulus observed 
at the same time point (Figure 5D). These features indicate 
impaired glomerular function induced by MMS.
AagTg/Parp1-/- mice exhibit MMs-induced 
podocyte injury
Given the apparent loss of glomerular filtration, 
we examined whether the AagTg/Parp1-/- mice displayed 
podocyte injury post-MMS by immunostaining for Wilm’s 
tumor 1 (WT1) protein, a podocyte marker. MMS-treated 
AagTg/Parp1-/- mouse kidneys exhibited a decreased 
number of WT1-stained cells. No significant change was 
observed in MMS-treated WT mice (Figure 6A-6B). 
Furthermore, we investigated a potential alteration in the 
slit diaphragm by immunostaining for Podocin. MMS-
treated AagTg/Parp1-/- mice exhibit diminished staining 
of Podocin, consistent with reduced glomerular filtration 
(Figure 6C). 
Electron-microscopy (Figure 6D) revealed that 
WT mice (untreated and14d post-MMS) had normal 
Figure 5: AagTg/Parp1-/- mice exhibit clinical signs of kidney damage. Serum levels of A. blood urea nitrogen (BUN), B. 
creatinine, and C. albumin were measured in untreated (n = 3-4), 14 days post-MMS treatment (75 mg/kg) (n = 5-6), and when mice 
exhibit morbidity (n = 3). For the moribund time point, a control WT mouse was assayed with each AagTg/Parp1-/- mouse. D. Silver stain 
visualization of protein content in urine of WT and AagTg/Parp1-/-  in untreated conditions and 7 days following MMS treatment (75 mg/
kg). 
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Figure 6: Podocyte damage is observed following MMS treatment in AagTg/Parp1-/- mice. A. Immunofluorescence staining 
of WT1-positive podocytes in WT and AagTg/Parp1-/- mice, untreated and 14 days following MMS treatment (75 mg/kg). A representative 
image of n = 3 mice is shown. Magnification is 600X (scale bar 10 µm). B. Quantitation of podocytes (the % of cells stained with both 
WT1 and DAPI/total number of DAPI positive cells in the glomerulus) is shown. Eight glomeruli were counted on each section from n = 
3-4 mice/condition. C. Immunofluorescence staining of Podocin in WT and AagTg/Parp1-/- mice in untreated and 14 days following MMS 
treatment (75 mg/kg). Magnification is 600X (scale bar 10 µm). D. Transmission electron microscopy (TEM) of WT and AagTg/Parp1-
/- mice, untreated and 14 days following MMS treatment (75 mg/kg). P, podocytes; fp, foot processes; cl, capillary lumen; B, Bowman’s 
capsule; GBM, glomerular basement membrane; PEC, parietal epithelial cell.
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glomerular tuft architecture comprised of well-organized 
capillary loops, Bowman’s capsule and flat parietal 
epithelial cells (PECs). Podocytes looked healthy with 
numerous well-organized foot processes. Untreated 
AagTg/Parp1-/- mouse kidneys appeared similar to the WT 
controls in ultrastructural morphology of glomerular tufts. 
However, MMS-treated AagTg/Parp1-/- mouse kidneys 
(14d) showed ultrastructural alterations consistent with 
the main histological alterations observed in the podocytes 
and PECs. As shown in Figure 6D, PECs and podocytes 
were markedly hypertrophied by the presence of multiple 
intracytoplasmic medium-to-large-sized membrane-
bound vacuoles. These vacuoles were mostly empty or 
occasionally contained pale to electron-dense irregular 
granular to amorphous material. The capillary tufts were 
distorted and compressed of numerous large distinct 
vacuoles within the podocyte foot processes. Extensive 
flattening and alteration of podocyte foot processes was 
observed. There was also a discernible reduction in the area 
of capillary loop and fusion between the large vacuolated 
Figure 7: Female AagTg/Parp1-/- mice are protected from MMS-mediated kidney damage. A. Kaplan Meier survival curves 
are shown for female (n = 14) and male (n = 16) AagTg/Parp1-/- mice following treatment with MMS (75 mg/kg). B. BW, as percent of 
initial BW, is shown for female AagTg/Parp1-/- (n = 14) and male AagTg/Parp1-/- (n = 16) mice following treatment with MMS (75 mg/
kg). C. H&E-stained images from kidneys are shown for female and male AagTg/Parp1-/- mice 14 days following MMS treatment (75 mg/
kg). Magnification is 600x (scale bar 10 µm). D. Total histopathology scores for glomerular damage (podocyte/parietal cell hyperplasia/
hypertrophy, vacuolation, capillary lumen collapse, tuft adhesions/sclerosis) and tubular damage (degeneration, cast formation, hyperplasia) 
is shown for female and male mice 14 days post-MMS treatment (75 mg/kg). Scores in a AagTg/ Parp1-/- male is also presented in Figure 
4B-4D.
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PECs and podocytes at the urinary pole, resulting in loss 
of urinary space. These observations confirm that AagTg/
Parp1-/- mice exhibit severe morphological and functional 
podocyte damage post-MMS. 
Female AagTg/Parp1-/- mice are protected from 
MMs-induced nephrotoxicity
An unexpected sexual dimorphism became apparent 
in MMS-treated female AagTg/Parp1-/- mice. MMS-
induced whole-animal toxicity was reduced in AagTg/
Parp1-/- female mice. The MMS LD50 for AagTg/Parp1
-
/- female mice is 80 mg/kg, whereas that for AagTg/Parp1-
/- male mice is 66 mg/kg. Furthermore, in contrast with 
the morbidity observed in male AagTg/Parp1-/- mice, 
female AagTg/Parp1-/- mice exhibited no body weight 
decrease and survived 30d post-MMS (75 mg/kg, Figure 
7A-7B). Histopathological analysis confirmed complete 
protection against kidney damage in MMS-treated female 
versus male AagTg/Parp1-/- mice (Figure 7C-7D). The 
renoprotective roles of estrogen are well-established in 
both mice [24, 25] and humans [26, 27]; our data suggest 
that estrogen may also be protective against alkylation-
induced nephrotoxicity in AagTg/Parp1-/- mice. Indeed, 
chronic 17b-estradiol treatment (E2 pellets) completely 
protected 6 out of 8 male mice against MMS-induced 
kidney damage (Supplemental Figure 5). The remaining 
2 mice showed only a mild pathology with few alterations 
of tubules and few affected glomeruli. Moreover, MMS-
mediated nephrotoxicity in males is not a consequence of 
the genetic background or strain, as AagTg/Parp1-/- mice 
on a pure 129S background exhibit kidney functional 
abnormalities similar to that of AagTg/Parp1-/- mice 
on a C57Bl/6J:129S mixed background (Supplemental 
Figure 6). This finding is especially relevant because 
genetic background has previously been shown to modify 
susceptibility to glomerular disorders [28, 29]. 
 DIscUssION
Although protected from MMS-induced toxicity 
in a variety of tissues, AagTg/Parp1-/- mice eventually 
succumb to whole-animal lethality at lower MMS 
doses in comparison to AagTg mice. This increased 
lethality was dependent on imbalanced BER, caused by 
increased Aag levels, since the MMS LD50 in Parp1
-/- 
mice expressing normal Aag levels is equivalent to that 
in WT mice. Interestingly, when BER is imbalanced by 
increased Aag activity, there are obvious tissue-specific 
differences with respect to whether Parp1 deficiency 
suppresses or exacerbates toxicity. Parp1 deficiency 
protects AagTg mice against MMS-induced tissue damage 
in the cerebellum, pancreas, spleen and retina [12], but 
enhances MMS-induced kidney damage. We examined 
a multitude of tissues in AagTg/Parp1-/- mice post-MMS 
and only found histological abnormalities in the kidney. 
It is possible that with time, additional tissues could 
display similar damage and that the rapid development 
of kidney disease prevents observation of such damage. 
Controlling Aag expression in a tissue-specific manner 
will help to determine whether other tissues exhibit 
MMS-mediated toxicity in the absence of Parp1 at longer 
time points. Neither increased Aag activity, nor Parp1 
deficiency alone resulted in susceptibility to kidney 
damage, but rather the combination of both gave rise to 
this severe kidney phenotype post-MMS treatment. We 
found that AagTg/Parp1-/- mice as well as AagTg mice 
generate more BER intermediates, i.e. AP sites, than WT 
mice post-MMS treatment. However, in AagTg mice, the 
higher accumulation of AP sites is compensated by higher 
levels of Parp activity compared to WT. In both, WT and 
AagTg mice, Parp activity returns to basal levels within 48 
hours when all lesions have likely been repaired. Unlike 
AagTg mice, AagTg/Parp1-/- mice do not show any Parp 
activity, suggesting that Parp deficiency is a limiting 
step in subsequent processing of BER intermediates 
and that the accumulation of BER intermediates, due 
to increased Aag activity and Parp deficiency, might be 
the cause of kidney toxicity. Our results are especially 
relevant given the fact that AAG levels can vary >10-fold 
in the human population (at least in lymphocytes) [12, 
16, 17] and given the recent surge in the use of PARP 
inhibitors in combination with chemotherapeutic agents. 
As nephrotoxicity can be the rate-limiting side effect in 
a subset of chemotherapeutic agents, these findings may 
have important clinical relevance [30]. 
In contrast to our finding that MMS induces 
nephrotoxicity in Parp1-/- and Parp-inhibited AagTg 
mice, several other models of kidney damage have 
demonstrated protection under conditions of genetic or 
pharmacologic Parp depletion. Parp1 depletion protects 
against nephrotoxicity induced by the chemotherapeutic 
agent, cisplatin [31, 32], diabetic nephropathy [33, 34] and 
the necrosis associated with renal ischemia/reperfusion 
[35, 36]. The MMS-induced nephrotoxicity in AagTg/
Parp1-/- mice was unexpected and to our knowledge has 
not been previously described. This finding suggests that 
Parp1 deletion or Parp inhibition may not give rise to the 
same outcomes across all tissues and experimental models, 
making it increasingly important to consider the clinical 
consequences of PARP inhibition in cancer treatment. 
Parp1 is a multi-functional protein, exhibiting many 
functions independent of its role in DNA repair [37]. It 
is possible that a DNA repair-independent Parp1 function 
contributes to the phenotype described here. For example, 
Parp1 plays a role in modulating inflammation [38, 39] 
and although there is no evidence of altered immune 
cell recruitment to the glomeruli, it remains possible 
that immune system changes contribute to this severe 
glomerular phenotype. Indeed, autoimmune disorders, 
such as lupus nephritis, routinely result in glomerular 
Oncotarget44961www.impactjournals.com/oncotarget
lesions with some of the characteristics we observe [40]. 
Strikingly, female AagTg/Parp1-/- mice were 
completely protected from MMS-mediated nephrotoxicity. 
Males (in both human and animal models) are more prone 
to kidney disease [41, 42]. Indeed, epidemiological studies 
identified male sex as a risk factor for kidney disease 
[43]. Consistent with this, female mice are protected 
from ischemic renal injury and diabetic nephropathy, and 
estrogen provides protection against ischemia-reperfusion 
renal injury and age-related kidney decline [44-46], but 
does not protect against cisplatin-mediated nephrotoxicity 
[47]. Specifically, stimulation of estrogen receptors 
protects against podocyte damage and death both in vitro 
and in vivo [48, 49]. Not only is estrogen protective, 
but testosterone potentiates renal injury [50-53]. Here, 
we show that estrogen treatment protects male mice 
from alkylation-induced nephrotoxicity. These findings 
further support the role of estrogen in protection against 
kidney disease. However, in addition to sex steroids, 
sexual dimorphisms in renal morphology and physiology 
[54, 55] may also contribute to the protection of female 
AagTg/Parp1-/- mice from MMS-mediated kidney 
disease. Additionally, it has been described previously 
that female and male mice exhibit different responses 
to Parp1 deletion or Parp inhibition in mouse models of 
endotoxemia and nephrotoxic serum-induced nephritis 
[56, 57]. These data further underscore the recent push for 
investigating and understanding sex differences in basic 
and clinical science [58-61]. 
The sexual dimorphism in our model may be 
explained by the interaction of Aag and Parp1 with 
estrogen receptor-α (ERα) [62, 63]. A direct interaction 
between Aag and ERα has been described; binding of 
Aag and ERα causes increased catalytic activity of Aag 
and decreased ERα-mediated transcription [62]. Parp1 
has been shown to bind and PARylate ERα, leading 
to increased binding of ERα to the estrogen response 
element in the promoter of target genes, thus promoting 
ERα-mediated transcription [63]. Together, these findings 
suggest that a direct interaction between Aag and/or 
Parp1 with estrogen receptors could lead to changes in 
DNA repair and/or gene expression, explaining the sexual 
dimorphism of MMS-mediated nephrotoxicity in mice. 
Numerous existing models of acquired podocyte 
diseases are used to explore human renal diseases, however 
all models have both advantages and disadvantages [14]. 
We present here a new model that may provide insight into 
the mechanisms of podocyte injury and death following 
treatment with alkylating agents.
MAtErIALs AND MEtHODs
Animals and treatments
Parp1-/- mice were purchased from Jackson 
Laboratories [64]. Aag transgenic (AagTg) mice were 
described previously [12, 13, 65]. All experiments were 
performed in mixed background mice (C57Bl/6J:129S) 
unless otherwise stated. All animal procedures were 
performed according the NIH guide for the Care and Use 
of Laboratory Animals.
Approximate LD50 was determined as in Deichmann 
and LeBlanc [66]. MMS was injected intraperitoneally. 
ABT-888 (10 mg/kg, Selleck Chemicals Inc) was 
administered by oral gavage 1 hour before and 5 days after 
MMS treatment. For estrogen treatment, 17b-estradiol 
pellets (E2, 0.1 mg/21 days release, Innovative Research 
of America) were implanted s.c. in the dorsal neck region 
of adult male mice. MMS was administered 3 days after 
implants. 
AP sites and PARP activity measurement
DNA was isolated using Roche kit according to 
the manufacturer’s instructions with precautions taken 
to avoid overheating of the DNA solution (proteinase 
K step 10 min at 55 0C). AP sites were determined by 
using the DNA Damage Quantification Kit (Dojindo) and 
performed according to the manufacturer’s instructions. 
Parp activity was determined by using the HT PARP in 
vivo Pharmacodynamic Assay II (Trevigen) according to 
the manufacturer’s instructions. 
serum analytes and albumin gel electrophoresis
Whole blood was collected via cardiac puncture and 
placed in BD microtainer serum separator tubes (VWR). 
Blood samples were then centrifuged for 5 minutes 
at 2000 x g to separate serum. Idexx Laboratories, Inc. 
(North Grafton, MA) performed serum chemistry analysis. 
Two μL of urine was denatured and run on a SDS-
PAGE gel and proteins were visualized using ProteoSilver 
Plus Silver Staining Kit (Sigma).
Electron microscopy
Tissue processing and imaging was performed by 
the W.M. Keck Microscopy Facility at the Whitehead 
Institute (MIT). Kidney cortex was fixed in 2.5% 
gluteraldehyde, 3% paraformaldehyde with 5% sucrose 
in 0.1 M sodium cacodylate buffer (pH 7.4), post-fixed 
in 1% osmium tetroxidein veronal-acetate buffer, stained 
in block overnight with 0.5% uranyl acetate in veronal-
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acetate buffer (pH 6.0) and then embedded in Embed-812 
resin. Ultrathin sections were cut from blocks on a Leica 
Ultracut UCT microtome with a Diatome diamond knife. 
The sections were examined using a FEI Tecnai Spirit at 
80 keV. 
Histopathology
Tissues were processed by the Histology Core 
Facility at the David H. Koch Institute for Integrative 
Cancer Research (MIT); they were paraffin-embedded, 
sectioned at 5 μm, and stained with hematoxylin and eosin 
(H&E), or Periodic Acid-Schiff (PAS). Phosphotungstic 
acid-haematoxylin (PTAH) staining was performed at 
the Division of Comparative Medicine (MIT). All H&E 
stained slides were blindly analyzed by a pathologist 
(R.T.B). Renal lesions were blindly scored by a pathologist 
(S.M.) using criteria listed in Supplemental Table 1. 
Immunofluorescence
Deparaffinized tissue sections (5 μm) were thermally 
processed for epitope retrieval using a Prestige Medical 
2100-Retriver. Sections were permeabilized in PBS-T (1x 
PBS + 0.1% Triton X-100, three times for 5 minutes each 
), incubated with 1x PBS-T plus 10% goat serum for 1 
hour and then stained with either anti-WT1antibody (Santa 
Cruz) or anti-podocin (Sigma) overnight at 4oC. Nuclear 
counterstaining was done using DAPI. The number of 
glomerular DAPI- and WT1-stained cells were counted 
using ImageJ. 
statistics
Statistical analyses were performed using GraphPad 
Prism software. Statistical significance was determined 
using unpaired t-test. Kaplan-Meier survival curves were 
generated and survival differences determined using the 
Log-Rank test. Data are represented as mean +/- SEM. A 
p-value is considered significant if less than 0.05.
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